MS-N182 · Nutrition and sleep support · Appraised October 30, 2026

Anti-inflammatory dietary education for sleep during breast-cancer chemotherapy

Aliases: E-DII-guided anti-inflammatory dietary education

Evidence at a glance

Question: Can anti-inflammatory dietary education reduce sleep disturbance during breast-cancer chemotherapy?
Finding: A 132-participant randomized trial reported better sleep scores and quality of life after 12 weeks. The full text was not accessible in this appraisal, so the precise food prescription, adherence and adverse-event details remain unverified.
Evidence label: Promising randomized signal; abstract-limited
Benefit: Mean PSQI improvement favored dietary education by 2.10 points, with fewer completers remaining above the study’s sleep-disturbance threshold.
Certainty: Low to moderate. Intention-to-treat modeling was reported, but the threshold comparison was completer-only and intervention details could not be fully appraised.
Risk: Adverse effects and weight change were not reported in the abstract. Dietary restriction during chemotherapy can worsen intake or weight loss if poorly designed.
Cancer-control boundary: Changes in sleep or inflammatory biomarkers do not establish tumor response, recurrence prevention or survival benefit.

Study details

Intervention: Twelve-week dietary-education program guided by the energy-adjusted dietary inflammatory index; exact foods and counseling intensity were not verified from the abstract.
Population: People with breast cancer, sleep disturbance and ongoing chemotherapy.
Design and comparator: Randomized controlled trial; dietary education versus usual care.
Sample: 132 randomized; 116 (87.9%) completed the 12-week assessment.
Primary outcome: Pittsburgh Sleep Quality Index at 12 weeks.
Results: Adjusted PSQI difference −2.10 points (95% CI −3.01 to −1.18). Among completers, 49.2% versus 78.9% remained at PSQI ≥8. Quality-of-life score also favored intervention by 14.07 points (95% CI 8.61–19.52).
Secondary findings: Dietary-inflammatory score and several inflammatory biomarkers changed, but biomarkers are not patient-centered cancer-control outcomes.
Limitations: Abstract-level appraisal; single study; completer analysis for the threshold result; self-reported sleep; clinical importance and safety details incompletely reported.
Funding and conflicts: National Natural Science Foundation of China grant 81703222; authors declared no competing interests.

Practical safety context

During chemotherapy, sleep goals should not come at the expense of calories, protein, hydration or food safety. People losing weight or muscle need individualized oncology-dietitian input before making restrictive changes.

Questions for the care team

Am I losing weight or muscle, and would restriction be unsafe?
What foods and counseling were actually tested?
Could a dietitian adapt the approach to treatment symptoms and medications?

Primary sources

Last literature search: October 30, 2026 · Record appraisal: October 30, 2026

Educational evidence summary, not medical advice. Do not change cancer treatment or supportive medications without discussing the decision with the treating team.